A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

270 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2019-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recombinant hemagglutinin has been shown to induce protective neutralising antibodies against avian influenza virus but is relatively non-immunogenic. An ideal pandemic avian influenza influenza vaccine would combine hemagglutinin antigen with an appropriate adjuvant to increase its immunogenicity. This Phase 1 study will collect preliminary human safety and efficacy data on combined formulations of recombinant hemagglutinin with Advax adjuvant formulations administered by intramuscular injection

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Study of Pandemic Influenza Vaccine

NCT00320346

Influenza

COMPLETED PHASE2

Study of a Pandemic Influenza Vaccine in Elderly Participants

NCT00376402

Influenza

COMPLETED PHASE2

Recombinant H7 Hemagglutinin Influenza Vaccine Trial

NCT03038776

Influenza, Avian

COMPLETED PHASE1

Study of a Pandemic Influenza Vaccine

NCT00136331

Influenza

COMPLETED PHASE1

Study of a Pandemic Influenza Vaccine in Children

NCT00370864

Influenza

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a study to test new vaccine formulations against pandemic avian influenza ("bird flu"). Bird flu is a potentially deadly disease that is caused by influenza virus from birds. It is not the same as the common seasonal flu for which there is a seasonal vaccine released around March each year. To date, bird flu due to the H5N1 strain of influenza virus has infected over 500 people mainly in Asia resulting in death in more than half the cases. More recently there has been an outbreak of another bird flu virus in China known as H9N7 that is also highly lethal when it infects humans. Vaccination is the single most effective measure to prevent infection from bird flu viruses such as H5N1 or H9N7 should such a pandemic occur. In the event of a major bird flu pandemic outbreak, vaccine supplies are likely to be very limited, as there is not currently sufficient manufacturing capacity to provide enough vaccine quickly for the whole population. Research is needed on how to make the pandemic flu vaccine more effective but also how to stretch vaccine supplies using a strategy called 'antigen-sparing'. This can potentially be achieved by using an important ingredient called an 'adjuvant'. Adjuvants act by stimulating the immune system to make vaccines more effective. This study will test Advax adjuvants which are based on delta inulin in combination with recombinant hemagglutinin from the H5N1 influenza virus serotype.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HA 45ug

recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses

Group Type EXPERIMENTAL

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

recombinant influenza hemagglutinin

HA 45ug+Advax1

recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses

Group Type EXPERIMENTAL

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

recombinant influenza hemagglutinin

Advax1

Intervention Type BIOLOGICAL

Delta inulin adjuvant formulation 1

HA 45ug+Advax2

recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses

Group Type EXPERIMENTAL

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

recombinant influenza hemagglutinin

Advax2

Intervention Type BIOLOGICAL

Delta inulin adjuvant formulation 2

HA 15ug+Advax1

recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses

Group Type EXPERIMENTAL

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

recombinant influenza hemagglutinin

Advax1

Intervention Type BIOLOGICAL

Delta inulin adjuvant formulation 1

HA 15ug+Advax2

recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses

Group Type EXPERIMENTAL

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

recombinant influenza hemagglutinin

Advax2

Intervention Type BIOLOGICAL

Delta inulin adjuvant formulation 2

HA 5ug+Advax1

recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses

Group Type EXPERIMENTAL

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

recombinant influenza hemagglutinin

Advax1

Intervention Type BIOLOGICAL

Delta inulin adjuvant formulation 1

HA 5ug+Advax2

recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses

Group Type EXPERIMENTAL

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

recombinant influenza hemagglutinin

Advax2

Intervention Type BIOLOGICAL

Delta inulin adjuvant formulation 2

HA 2.5ug+Advax2

recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses

Group Type EXPERIMENTAL

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

recombinant influenza hemagglutinin

Advax2

Intervention Type BIOLOGICAL

Delta inulin adjuvant formulation 2

HA 15ug

recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses

Group Type EXPERIMENTAL

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

recombinant influenza hemagglutinin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

recombinant influenza hemagglutinin

Intervention Type BIOLOGICAL

Advax1

Delta inulin adjuvant formulation 1

Intervention Type BIOLOGICAL

Advax2

Delta inulin adjuvant formulation 2

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ambulatory males or females aged 18 years and over
* Able to provide written informed consent
* Willing and able to comply with the protocol for the duration of the study.
* Not planning to have seasonal influenza vaccine within 2 months from the time of the first trial immunization

Exclusion Criteria

* Pregnant or lactating women.
* Women of childbearing potential unless using a reliable and appropriate contraceptive method.
* Receipt of another investigational agent within 28 days preceding initiation of treatment.
* Any other serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes